Anders Pedersen
Overview
Explore the profile of Anders Pedersen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
770
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Herman K, Holyer I, Humphries D, Roper J, Peterson K, Zetterberg F, et al.
Pharmacology
. 2025 Feb;
:1-14.
PMID: 39900003
Introduction: Galectin-1 (Gal-1) is a lectin that has been shown to be involved in a number of pro-tumorigenic mechanisms and has also been shown to be immune-suppressive. Therefore, pharmacological blockade...
2.
Peterson K, Nilsson U, Gravelle L, Holyer I, Jansson K, Kahl-Knutson B, et al.
J Med Chem
. 2024 Dec;
67(24):21905-21915.
PMID: 39668131
The interest in galectin-3 as a drug target in the cancer and fibrosis space has grown during the past few years with several new classes of compounds being developed. The...
3.
Herman K, Holyer I, Humphries D, Adamska A, Roper J, Peterson K, et al.
Int J Mol Sci
. 2024 Nov;
25(22).
PMID: 39596018
Galectin-1 is implicated in several pro-tumourigenic mechanisms and is considered immune-suppressive. The pharmacological inhibition of galectin-1 may be beneficial in cancers in which galectin-1 is overexpressed and driving cancer progression....
4.
MacKinnon A, Humphries D, Herman K, Roper J, Holyer I, Mabbitt J, et al.
Eur J Pharmacol
. 2024 Nov;
985:177077.
PMID: 39528104
Background And Purpose: Galectin-3 (Gal-3) is a pro-fibrotic β-galactoside binding lectin highly expressed in fibrotic liver and implicated in hepatic fibrosis. GB1107 is a novel orally active Gal-3 small molecule...
5.
Kim H, Kretz L, Ronin C, Starck C, Roper J, Kahl-Knutson B, et al.
Int J Mol Sci
. 2024 Jun;
25(12).
PMID: 38928409
The beta-galactoside-binding mammalian lectin galectin-1 can bind, via its carbohydrate recognition domain (CRD), to various cell surface glycoproteins and has been implicated in a range of cancers. As a consequence...
6.
Zetterberg F, Peterson K, Nilsson U, Andreasson Dahlgren K, Diehl C, Holyer I, et al.
J Med Chem
. 2024 May;
67(11):9374-9388.
PMID: 38804039
We have previously described a new series of selective and orally available galectin-1 inhibitors resulting in the thiazole-containing glycomimetic GB1490. Here, we show that the introduction of polar substituents to...
7.
Mabbitt J, Holyer I, Roper J, Nilsson U, Zetterberg F, Vuong L, et al.
Front Immunol
. 2023 Sep;
14:1250559.
PMID: 37701441
Background: Galectin-3 (Gal-3) is a β-galactoside-binding lectin that is highly expressed within the tumor microenvironment of aggressive cancers and has been suggested to predict a poor response to immune checkpoint...
8.
Cedeno M, Murillo-Saich J, Coras R, Cedola F, Brandy A, Prior A, et al.
Metabolomics
. 2023 Apr;
19(4):37.
PMID: 37022535
Background: Seronegative elderly-onset rheumatoid arthritis (EORA) and polymyalgia rheumatica (PMR) have similar clinical characteristics making them difficult to distinguish based on clinical features. We hypothesized that the study of serum...
9.
Kim H, Weidner N, Ronin C, Klein E, Roper J, Kahl-Knutson B, et al.
SLAS Discov
. 2023 Mar;
28(5):233-239.
PMID: 36990319
Galectin-3 is a beta-galactoside-binding mammalian lectin that is one of a 15-member galectin family that can bind several cell surface glycoproteins via its carbohydrate recognition domain (CRD). As a result,...
10.
Aslanis V, Slack R, MacKinnon A, McClinton C, Tantawi S, Gravelle L, et al.
Cancer Chemother Pharmacol
. 2023 Mar;
91(3):267-280.
PMID: 36914828
Purpose: Galectin-3, a β-galactoside-binding lectin, plays a key role in several cellular pathways involved in chronic inflammation, heart disease and cancer. GB1211 is an orally bioavailable galectin-3 inhibitor, developed to...